IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model
Open Access
- 9 September 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (37)
Abstract
Chagas disease is a neglected disease that affects millions of people from the Latin American region. Current nitroheterocyclic therapies suffer from long treatment duration and safety-related treatment discontinuations. A safe, short course therapy would significantly benefit Chagas patients. Here, we report the comprehensive biological, structural, pharmacodynamic, and pharmacokinetic characterization of IID432, an optimized cyanotriazole with superior potency, favorable pharmacokinetics, and improved safety profile compared to the lead compound CT1. IID432 is a fast-acting, parasite-selective topoisomerase II poison that achieves sterile cure after a single oral dose in a murine model of chronic Trypanosoma cruzi infection. Mechanistically, IID432 stabilizes the parasite TcTopoII-DNA cleavage complex by covalently engaging a parasite-specific cysteine (Cys477), thereby conferring selectivity over the human TOP2A. IID432 displays favorable oral pharmacokinetics, with no off-target activity on human topoisomerases. Brief exposure of IID432 rapidly induces parasite-specific DNA damage and produces sterilizing activity in vitro and in vivo without recrudescence. Together, these findings identify IID432 as a first-in-class, parasite-selective covalent topoisomerase poison with a potential to significantly shorten treatment duration for T. cruzi infections.Keywords
Funding Information
- Wellcome Trust (219639/Z/19/Z)
This publication has 24 references indexed in Scilit:
- Discovery of IID432 for Chagas Disease: A Cyanotriazole Inhibitor of Trypanosoma cruzi Topoisomerase II Achieves Sterile Cure After Short-Term Treatment in a Chronic Infection ModelJournal of Medicinal Chemistry, 2026
- Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023The Lancet Infectious Diseases, 2025
- Challenges and advancements in the development of vaccines and therapies against Chagas diseaseThe Lancet Microbe, 2024
- Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trialThe Lancet Infectious Diseases, 2024
- Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome InhibitorsJournal of Medicinal Chemistry, 2023
- Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primatesNature Microbiology, 2022
- New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trialThe Lancet Infectious Diseases, 2021
- Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitorsNature Microbiology, 2020
- Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sicknessNature, 2016
- Trypanosomal histone γH2A and the DNA damage responseMolecular and Biochemical Parasitology, 2012